TAAR1 and schizophrenia: The first developed TAAR1 agonists, RO6889450 (Ralmitaront) and SEP-363856 (Ulotaront), have already been tested in phase II clinical trials for the treatment of schizophrenia, with Ulotaront currently being tested in phase III clinical trials [11].